# Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

> **NCT02963610** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Relapsed or Refractory Solid Tumors
- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02963610
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-29
- **Primary completion:** 2017-10-03
- **Final completion:** 2018-03-20
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study terminated prematurely due to funding/support being withdrawn by grantor
- **Last updated:** 2021-12-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963610, "Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02963610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*